-
Nov 12, 2024 | 
litigate.com | Brian Kolenda |Andrew Moeser |Sana Halwani |Matthew Lerner
Canada’s leading litigation firm has reaffirmed its Tier 1 ranking in Dispute Resolution in Legal 500 Canada. Based on in-depth research, client feedback, and interviews with leading lawyers in the industry, Lenczner Slaght also continues to be recognized for its litigation excellence in Construction, Insurance, Intellectual Property, and Restructuring and Insolvency. Dispute ResolutionHall of Fame Tom Curry Peter GriffinLeading Partners Matthew B.
-
Oct 27, 2024 | 
litigate.com | Andrew Moeser
Andrew Moeser was invited to share his expertise at the University of Toronto’s annual Patent Colloquium. Andrew will present on the panel titled, Ambiguity and indefiniteness.
-
May 20, 2024 | 
mondaq.com | Andrew Moeser
A desire to expedite patent disputes may result in a party
pursuing summary adjudication. We have previously commented on a
number of cases relating to the use of summary proceedings for
resolving patent cases in Canada.
-
May 15, 2024 | 
litigate.com | Jordana Sanft |Andrew Moeser
A desire to expedite patent disputes may result in a party pursuing summary adjudication. We have previously commented on a number of cases relating to the use of summary proceedings for resolving patent cases in Canada.
-
May 7, 2024 | 
mondaq.com | Sana Halwani |Jordana Sanft |Andrew Moeser
The Federal Court of Appeal's decision in Steelhead v ARC upholds Justice
Manson's summary trial decision finding no infringement
by ARC Resources of Steelhead's 085 Patent. In summary, the FCA
held that the marketing of an apparatus that – if built
– would infringe the 085 Patent did not constitute
"use" (or "exploiter" in the French version)
under of the Patent Act, and therefore could not
be infringement.
-
Apr 29, 2024 | 
litigate.com | Sana Halwani |Jordana Sanft |Andrew Moeser
The Federal Court of Appeal’s decision in Steelhead v ARC upholds Justice Manson’s summary trial decision finding no infringement by ARC Resources of Steelhead’s 085 Patent. In summary, the FCA held that the marketing of an apparatus that – if built – would infringe the 085 Patent did not constitute “use” (or “exploiter” in the French version) under of the Patent Act, and therefore could not be infringement.
-
Mar 12, 2024 | 
litigate.com | Andrew Moeser
March 26, 2024 Patent and Trademark Case Law Review Series Andrew Moeser was invited to present at the Intellectual Property Institute of Canada’s Patent and Trademark Case Law Review Series. Andrew will discuss leading court decisions on core trademark issues, related to “Section 45”.
-
Mar 1, 2024 | 
mondaq.com | Sana Halwani |Andrew Moeser
If your 2024 has been too busy to keep up with caselaw, below we
summarize and provide the key takeaways from pharmaceutical patent
decisions that have been issued from the Federal Court and Federal
Court of Appeal in the last two months.
Summary: Apotex filed two abbreviated new drug
submissions (ANDSs) comparing their paliperidone product to
Janssen's INVEGA SUSTENNA product.
-
Feb 22, 2024 | 
litigate.com | Sana Halwani |Andrew Moeser
If your 2024 has been too busy to keep up with caselaw, below we summarize and provide the key takeaways from pharmaceutical patent decisions that have been issued from the Federal Court and Federal Court of Appeal in the last two months. Two NOAs Is Not Better than One: Janssen v Apotex (December 22, 2023)Summary: Apotex filed two abbreviated new drug submissions (ANDSs) comparing their paliperidone product to Janssen’s INVEGA SUSTENNA product.
-
Jul 12, 2023 | 
mondaq.com | Andrew Moeser
Andrew Moeser will be sharing his expertise on
patent enforcement at the joint Intellectual Property Institute of Canada and
McGill University Summer IP Course. Andrew will lead a discussion
on Patent Enforement: Infringement, as well as participate on a
Mock Trial focused on Expert Reports and Cross-Examination of a
Witness.
Continue reading original source
The content of this article is intended to provide a general
guide to the subject matter.
